ClinicalTrials.gg
RecruitingNCT07326358Updated Jan 8, 2026

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

An observational study in Nasopharyngeal Neoplasms and Laryngeal Disease, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Ruijin Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Nasopharyngeal Neoplasms with a site in China — 22 open to participants now, 30 under way, 6 of them phase 3. Nasopharyngeal Neoplasms · China.

Planned enrollment
7th of 10
500 · median 836
Started
2025
with 5 others
Observational
10 of 83
2 open now
Primary completion
2026-12
later than 15 of 29 live
Registered
80th of 83
by date

Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 6 that started in 2025, is one of 10 observational ones, reaches primary completion later than 15 of the 29 other live ones, and was the 80th registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

22 of the 83 studies in Nasopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasopharyngeal Neoplasms with a site in China, or all of them as a file.
02

Study summary

An artificial intelligence-assisted system is trained and validated by collecting nasopharyngolaryngoscopy images from patients.

Read the detailed description

To address the clinical pain points of traditional nasopharyngolaryngoscopy, such as incomplete visualization, inaccurate identification, and unclear imaging, this study will retrospectively collect nasopharyngolaryngoscopy images and baseline information (including gender and age) of patients who underwent nasopharyngolaryngoscopy at participating centers for model training and validation. Deep learning algorithms will be applied to construct the model. The final clinical performance evaluation of the model will be conducted using an independent, prospectively collected test cohort.

03

Conditions studied

  • Nasopharyngeal Neoplasms
  • Laryngeal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Image data of patients who underwent nasopharyngolaryngoscopy and met the research requirements were collected from various sub-centers nationwide.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Underwent standard electronic nasopharyngolaryngoscopy;
  • Patients who underwent sampling have a clear pathological diagnosis;
  • Signed a written form.

Exclusion criteria

Exclusion Criteria:

  • Image quality is substandard with severe motion artifacts;
  • Lesion images are unclear and incomplete.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Model training and validation cohorts

    A deep learning model is trained using the training dataset and validated with the internal validation set.

    Other: Diagnostic

  • Prospective test cohort

    Patients are prospectively enrolled, nasopharyngolaryngoscopy examination videos are collected, and the video data are processed to form a prospective test dataset, which is then used for testing.

    Other: Diagnostic

Interventions

  • OtherDiagnostic

    The deep learning model is trained using the training dataset and tested with the internal validation set.

  • OtherDiagnostic

    The prospective dataset is used for the comparative testing of the model and physicians.

06

What researchers measure

Primary outcomes

  1. performance of lesion detection

    The area under the receiver operating characteristic curve (ROC-AUC) of the model for abnormal lesion detection

    Time frame: Within 3 months after the completion of prospective data collection

  2. performance of anatomic site recognition

    The average precision (AP) of the model for recognizing nasopharyngeal and laryngeal anatomic sites

    Time frame: Within 3 months after the completion of prospective data collection

Secondary outcomes

  1. Comparison of diagnostic performance between the model and physicians

    Differences in sensitivity, specificity, and overall accuracy between the AI model and endoscopists with different years of experience

    Time frame: Within 3 months after the completion of prospective data collection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 8, 2026
StartActual
Dec 12, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07326358
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Dec 12, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Bin Ye, MD PhD
Contact
aydyebin@126.com
+8615216616895

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion